Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia

被引:800
作者
Ren, R [1 ]
机构
[1] Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, Waltham, MA 02454 USA
关键词
D O I
10.1038/nrc1567
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Imatinib, a potent inhibitor of the oncogenic tyrosine kinase BCR-ABL, has shown remarkable clinical activity in patients with chronic myelogenous leukaemia (CML). However, this drug does not completely eradicate BCR-ABL-expressing cells from the body, and resistance to imatinib emerges. Although BCR-ABL remains an attractive therapeutic target, it is important to identify other components involved in CML pathogenesis to overcome this resistance. What have clinical trials of imatinib and studies using mouse models for BCR-ABL leukaemogenesis taught us about the functions of BCR-ABL beyond its kinase activity, and how these functions contribute to CML pathogenesis?
引用
收藏
页码:172 / 183
页数:12
相关论文
共 122 条
[1]  
Ahuja HG, 2001, GENE CHROMOSOME CANC, V30, P410, DOI 10.1002/1098-2264(2001)9999:9999<::AID-GCC1108>3.0.CO
[2]  
2-9
[3]   Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment [J].
Bhatia, R ;
Holtz, M ;
Niu, N ;
Gray, R ;
Snyder, DS ;
Sawyers, CL ;
Arber, DA ;
Slovak, ML ;
Forman, SJ .
BLOOD, 2003, 101 (12) :4701-4707
[4]  
BIERNAUX C, 1995, BLOOD, V86, P3118
[5]  
BOS JL, 1989, CANCER RES, V49, P4682
[6]   The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: Biologic significance and implications for the assessment of minimal residual disease [J].
Bose, S ;
Deininger, M ;
Gora-Tybor, J ;
Goldman, JM ;
Melo, JV .
BLOOD, 1998, 92 (09) :3362-3367
[7]   Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder [J].
Braun, BS ;
Tuveson, DA ;
Kong, N ;
Le, DT ;
Kogan, SC ;
Rozmus, J ;
Le Beau, MM ;
Jacks, TE ;
Shannon, KM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (02) :597-602
[8]   Gene expression profiling in chronic myeloid leukemia patients treated with hydroxyurea [J].
Bruchova, H ;
Borovanova, T ;
Klamova, H ;
Brdicka, R .
LEUKEMIA & LYMPHOMA, 2002, 43 (06) :1289-1295
[9]   A BCR-ABL(p190) fusion gene made by homologous recombination causes B-cell acute lymphoblastic leukemias in chimeric mice with independence of the endogenous bcr product [J].
Castellanos, A ;
Pintado, B ;
Weruaga, E ;
Arevalo, R ;
Lopez, A ;
Orfao, A ;
SanchezGarcia, I .
BLOOD, 1997, 90 (06) :2168-2174
[10]   Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease [J].
Chan, IT ;
Kutok, JL ;
Williams, IR ;
Cohen, S ;
Kelly, L ;
Shigematsu, H ;
Johnson, L ;
Akashi, K ;
Tuveson, DA ;
Jacks, T ;
Gilliland, DG .
JOURNAL OF CLINICAL INVESTIGATION, 2004, 113 (04) :528-538